Physician profile
Robert Doan
NPI 1063516300
$3,812.50
in general payments reported to CMS, 2019-2025
29 companies · $720 in 2025
The $720 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,743 · 2022: $312 · 2023: $401 · 2024: $635 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $664.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $658.85 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $367.60 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $243.43 | 2021-2025 | |
| Pfizer INC. | $216.40 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $202.51 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $194.53 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.39 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.23 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $113.47 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.92 | 2021-2022 | |
| Amarin Pharma, INC. | $87.83 | 2021 | |
| Vifor Pharma, INC. | $87.54 | 2021 | |
| Axsome Therapeutics, INC. | $82.59 | 2025 | Sunosi |
| Abbott Laboratories | $68.97 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58.41 | 2021-2022 | |
| Glaxosmithkline, LLC. | $49.10 | 2021 | |
| Biogen, INC. | $42.38 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.38 | 2021 | |
| Merck Sharp & Dohme LLC | $31.75 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $26.89 | 2025 | Neffy |
| Genentech USA, INC. | $24.10 | 2021 | |
| Astellas Pharma US INC | $20.45 | 2023 | Veozah |
| Medtronic, INC. | $20.42 | 2022 | |
| Exact Sciences Corporation | $19.41 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $18.75 | 2024 | Ajovy |
| Kowa Pharmaceuticals America, INC. | $17.08 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.69 | 2025 | Nuzyra |
| Currax Pharmaceuticals LLC | $14.16 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.